Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 0/523,558

Filing Date February 4, 2005

First Named Inventor Helen Francis-Lang

Art Unit 1652

Examiner Name SWOPE, Sheridan

(Use as many sheets as necessary)

ubstitute for form 1449A/PTO

SAT & THADEN

Sheet 1 of 3 Attorney Docket Number 05-940-F

	U. S. PATENT DOCUMENTS					
Examiner Cite No.1	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where . Relevant Passages or Relevant	
		Number-Kind Code ^{2 (d known)}	Applicant of Cited December	Figures Appear		
77	A1	us- 6,180,362	01/30/2001	Marc Duchesne et al.		
		US-				
		US-				
	·	US-				
		US-				
		US-			· · · · · · · · · · · · · · · · · · ·	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS						
	Examiner			Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials* N		No.'		MM-DD-YYYY			
_4	1				The U.S.A. as		
\mathcal{A}	$-\mathcal{U}$	A2	WO 01/88191	11/22/2001	Represented by the		
U					Department of Veter		
	_	ÁЗ	WO 01/66594	09/13/2001	Sugen, Inc., Plowman et al.		
	-	Å 4	WO 02/46384	06/13/2002	Incyte Genomics, Inc.		
		A 5	WO 01/53493	07/26/2001	Lexicon Genetics Inc.		
A)	A 6	WO 97/42222	11/13/1997	Cyclacel Limited Ball et al.		

Examiner Signature	SHERIDAN SWOPE, PH.D.	Date Considered	JUN 1 1 2007

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief.Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO Complete If Known **Application Number** 10/523,588 INFORMATION DISCLOSURE Filing Date February 4, 2005 STATEMENT BY APPLICANT First Named Inventor Helen Francis-Lang Art Unit 1652 (Use as many sheets as necessary) **Examiner Name** SWOPE, Sheridan Attorney Docket Number Sheet 2 05-940-F

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
& T	A7	KUSUDA J. et al.: "Cloning and Chromosome Mapping of the Human Casein Kinase I GAMMA3 Gene (CSNK1G3)," Cytogenetics and Cell Genetics, Basel, CH, Vol. 83m No. 1/2, 1998, pages 101-103, XP008052374.				
	A8_	KITABAYASHI A N et al.: "Cloning and Chromosomal Mapping of Human Casein Kinase I gamma 2 (CSNK1G2)," Genemics, Academic Prises, San Diego, US, Vol. 46, No. 1, November 15, 1997, pages 128–137, X1014439098.				
	A9	KUSUDA J. et al.: "Cloning, Extression analysis and chromosome mapping of human casein kinase 1 gamma 1 (CSNK1G1): Identification of two types of can encoding the kinase protein associated with neterogonous carboxy-terminal sequences" CYTOGENETICS and CELL GENETICS BASEL, CH, Vol. 90, 2000, pages 298-302, XP002977055.	,			
	A10	GROSS Stefan D. et al.: "A casein kinase I isoform is required for proper cell cycle progression in the fertilized mouse oocyte," JOURNAL of CELL SCIENCE, Vol. 110, NO. 24, December 1997, pages 3083-3090, XP002392918.				
		WANG Xiangmin et al.: "Prenylated isoforms of yeast casein kinase I, including the novel Yck3p, suppress the gcs1 blockage of cell proliferation from stationary phase," MOLECULAR AND CELLULAR BIOLOGY, Vol. 16. No. 10, 1996, pages 5375-5385, XP002392919.				
		GROSS S D et al.: " Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family," CELLULAR SIGNALING, ELSEVIER SCIENCE LTD, GB, Vol. 10, No. 10, November 1998, pages 699-711, XP002331674.				
*		MCKAY Renee M. et al.: "The casein kinase I family in Wnt signaling," DEVELOPMENTAL BIOLOGY, Vol. 235, No. 2, July 15, 2001, pages 388-396, XP002392920.				

Examiner Signature	SHERIDAN SWOPE, PH.D. PRIMARY EXAMINER	Date Considered	JUN 1 1 2007
-----------------------	--	--------------------	--------------

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not clauon is in conformance with MPEP 609. Uraw line inrough clauon if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

/PTO 24 MAR 2005

PTO/SB/08b(08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

te for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/523,588 02-04-2005 Filing Date First Named Inventor Francis-Lang Art Unit Examiner Name

(Use as many sheets as necessary)

EX03-057C-US of 2 Attorney Docket Number Sheet

		NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher oity and/or country where published.	T 2
	1	Guo,L., et al., Homo sapiens caecin kinase 1, gamma 1 (CSNK)G1), transcript variant 2, mRNA. Genbank identifier no: GI:11546730	/
	2	Strausberg,R. Homo sapiens, casein kinase 1, gamma 1, clone MGZ:19461 IMAGE:4123494, mRNA, complete cds. Genbank GI:16878051	
	3	Kawabata,A., et al., Homo sapiens cDNA: FLJ2330 fis, clane HEP11377. Genbank Gl:10439939	/
	4	Ansorge,W., et al, Homo sapiens mRNA; con DKFZp547 1617 (from clone DKFZp547K1617). Genbank GI:21733126	~
	5	Guo,L., et al. Homo sapiens casein kina) el gamma hisoform mRNA, complete cds. Genbank Gl:27375099	
	6	Mishra,S.K., et al. Homo sapit hs casein kirisse 1, gamma 2 (CSNK1G2), mRNA. Genbank Gl:21314777	
	7	Strausberg RL, et al. Hono sapiens casein kinase 1, gamma 2, mRNA (cDNA clone MGC:9354 IMAGE:3851613), complete cds. Genbank Gl:18088089	/
	8	Kitabayashi,A.N., a al. Homo sapiens casein kinase I gamma 2 primary transcript, complete cds. Genbank GI:2199528	
	9	Andersson B., et al. Homo sapiens clone CDABP0048 mRNA sequence. Genbank GI:9956036	/
	10	Kusada,J., et al. Homo sapiens casein kinase 1, gamma 3 (CSNK1G3), mRNA. Genbank GI:4758079	
	11/	Kusuda,J., et al. Homo sapiens casein kinase I gamma 3L (CSNK1G3L) mRNA, complete cds. Genbank Gi:4590041	

Examiner	SHERIDAN SWUPE, PH.D.	Date	
Signature	PRIMARY EXAMINER	Considered	JUN 1 1 2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PCT/PFO 24 MAR 2005

PTO/SB/08b(08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

TRADE BOOK Stitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

Complete if Known				
Application Number .	10/523,588			
Filing Date	02-04-2005			
First Named Inventor	Francis-Lang			
Art Unit				
Examiner Name				
Attorney Docket Number	EX03-057C-US			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2
····	12	Strausberg, R.L., et al. Homo sapiens casein kinase 1, gamma 3, mRMA con A cone MGC:48323 IMAGE:4817058), complete cds. Genbank GI:28837292	-
	13	Guo, L., et al. casein kinase 1, gamma 1 isoform S [Hodis sapiers]. Anbank Gl:11545751	
	14	Kitabayashi,A.N., et al. casein kirlase 14 ab ria 2 [Homa Sepiens]. Genbank Gl:5579454	
	15	Mishra,S.K., et al. casein kinase v, gamma 2 [Homo sapiens]. Genbank Gl:21314778	_
^	16	Kusuda,J., et al. casein kinase 1, gamma 3 [Homo sapiens]. Genbank Gl:4758080	7
25	17	Kusuda J, Hirai M, Tanuma R, Hashimoto K. Cloning, expression analysis and chromosome mapping of human casein kinase 1 gamma1 (CSNK1G1): identification of two types of cDNA encoding the kinase protein associated with heterologous carboxy-terminal sequences. Cytogenet Cell Genet. 2000;90(3-4):298-302.	
1	18	Kitabayashi AN, Kusuda J, Hirai M, Hashimoto K. Cloning and chromosomal mapping of human casein kinase I gamma 2 (CSNK1G2). Genomics. 1997 Nov 15;46(1):133-7.	
*	19	Zhai L, Graves PR, Robinson LC, Italiano M, Culbertson MR, Rowles J, Cobb MH, DePaoli-Roach AA, Roach PJ. Casein kinase I gamma subfamily. Molecular cloning, expression, and characterization of three mammalian isoforms and complementation of defects in the Saccharomyces cerevisiae YCK genes. J Biol Chem. 1995 May 26;270(21):12717-24.	

Evaminar	ONEDIDAN CHIODE DIAD	Date	4 1 2007
Examiner Signature	SHERIDAN SWOPE, PH.D.	Considered	JUN 1 1 2007
Signature	PRIMARY FXAMINER	Oorisiacica	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.